Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 3 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 3.
No closed vehicle here has both a stored price and a filed trust value to score it against.
2 vehicles on file, newest listing first
2 of 9 appear on more than one
Andrew Kucharchuk has served as our Chief Financial Officer since inception. He has served as CFO of Range I since June 2025. Mr. Kucharchuk also currently serves as Chief Financial Officer of Cero Therapeutics, Inc (Nasdaq: CERO). Previously, he served as the Chief Financial Officer of Theralink Technologies, Inc. (“Theralink”) (OTCMKTS: THER) from May 2023 until May 2024, and also served as President and Chief Financial Officer of Theralink from February 2016 until June 2020 and as Acting Chief Financial Officer of Theralink from June 2020 to September 2020. He served on the Board of Directors of Theralink from June 2020 until June 2024. In addition, Mr. Kucharchuk served as Chief Executive Officer and Chief Financial Officer of OncBioMune, Inc. (“OBMP”) prior to Theralink’s acquisition of OBMP. Mr. Kucharchuk also served as the Chairman and Chief Operating Officer Adhera Therapeutics, Inc. (OTCMKTS: ATRX) from July 2020 until September 2022 and its Chief Operations Officer from October 2022 to September 2024. Mr. Kucharchuk is a graduate of Louisiana State University and Tulane University’s Freeman School of Business, where he earned an MBA with a Finance Concentration.
This record is keyed to SEC CIK 0001654127 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 80 institutional-holder rows on these vehicles, under 42 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.